Involvement of endogenous cholecystokinin in tolerance to morphine antinociception in the nucleus accumbens of rats

Behavioural Brain Research

Volumn 173, Issue 1, 2006, Pages 116-121

  Xiong, Wei ^a   Yu, Long Chuan ^a  

^a National Laboratory of Biomembrane and Membrane Biotechnology   (China)

Author keywords

Antinociception; Cholecystokinin; Morphine; Nucleus accumbens; Tolerance

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; LY 225910; MORPHINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CHOLECYSTOKININ BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG INHIBITION; MALE; MORPHINE TOLERANCE; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; CHOLECYSTOKININ; DRUG TOLERANCE; MALE; MORPHINE; NUCLEUS ACCUMBENS; PAIN THRESHOLD; RATS; RATS, WISTAR;

EID: 33749988686     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.06.010     Document Type: Article

References (44)

1. Altier N., and Stewart J. Tachykinin NK-1 and NK-3 selective agonists induce analgesia in the formalin test for tonic pain following intra-VTA or intra-accumbens microinfusions. Behav Brain Res 89 (1997) 151-165
2. Baber N.S., Dourish C.T., and Hill D.R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39 (1989) 307-328
3. Becker C., Pohl M., Thiebot M.H., Collin E., Hamon M., Cesselin F., et al. Delta-opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin-like material by subchronic morphine in rats. Neuropharmacology 39 (2000) 161-171
4. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64 (1996) 535-543
5. Benedetti F., Amanzio M., and Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 346 (1995) 1231
6. Bernstein Z.P., Yucht S., Battista E., Lema M., and Spaulding M.B. Proglumide as a morphine adjunct in cancer pain management. J Pain Symptom Manage 15 (1998) 314-320
7. Crawley J.N., and Corwin R.L. Biological actions of cholecystokinin. Peptides 15 (1994) 731-755
8. Derrien M., Noble F., Maldonado R., and Roques B.P. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci Lett 160 (1993) 193-196
9. Dockray G.J. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 264 (1976) 568-570
10. Faris P.L., Komisaruk B.R., Watkins L.R., and Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219 (1983) 310-312
11. Farook J.M., McLachlan C.S., Zhu Y.Z., Lee L., Moochhala S.M., and Wong P.T. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus. Neurosci Lett 358 (2004) 215-219
12. Gall C., Lauterborn J., Burks D., and Seroogy K. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 403 (1987) 403-408
13. Han J.S., Ding X.Z., and Fan S.G. Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous anti-opioid substrates?. Neuropeptides 5 (1985) 399-402
14. Hill D.R., Campbell N.J., Shaw T.M., and Woodru G.N. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective non-peptide CCK antagonists. J Neurosci 7 (1987) 2967-2976
15. Hill D.R., Shaw T.M., and Woodru G.N. Species differences in the localization of "peripheral" type CCK receptors in rodent brain. Neurosci Lett 79 (1987) 286-298
16. Itoh S., Katsuura G., and Maeda Y. Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol 80 (1982) 421-425
17. Kombian S.B., Ananthalakshmi K.V., Parvathy S.S., and Matowe W.C. Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro. J Physiol 555 (2004) 71-84
18. Li J.J., Zhou X., and Yu L.C. Involvement of neuropeptide Y and Y1 receptor in antinociception in the arcuate nucleus of hypothalamus, an immunohistochemical and pharmacological study in intact rats and rats with inflammation. Pain 118 (2005) 232-242
19. Linderfors N., Linden A., Brene S., Sedvall G., and Persson H. CCK peptides and mRNA in the human brain. Prog Neurobiol 40 (1993) 671-690
20. Lucas G.A., Hoffmann O., Alster P., and Wiesenfeld-Hallin Z. Extracellular cholecystokinin levels in the rat spinal cord following chronic morphine exposure: an in vivo microdialysis study. Brain Res 82 (1999) 179-186
21. Maldonado R., Derrien M., Noble F., and Roques B.P. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport 4 (1993) 947-950
22. McCleane G.J. A phase 1 study of the cholecystokinin (CCK) B antagonist L-365 260 in human subjects taking morphine for intractable non-cancer pain. Neurosci Lett 332 (2002) 210-212
23. Millan M.J., Audinot V., Honore P., Bervoets K., Veiga S., and Brocco M. Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats. Eur J Pharmacol 388 (2000) 37-47
24. Mutt V., and Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. Cleavage with thrombin and with trypsin. Eur J Biochem 6 (1968) 156-162
25. Noble F., and Roques B.P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 58 (1999) 349-379
26. Noble F., Derrien M., and Roques B.P. Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109 (1993) 1064-1070
27. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, Sydney
28. Pohl M., Benoliel J.J., Bourgoin S., Lombard M.C., Mauborgne A., Taquet H., et al. Regional distribution of calcitonin gene-related peptide-, substance P-, cholecystokinin-, Met5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effetcs of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55 (1990) 1122-1130
29. Pommier B., Beslot F., Simon A., Pophillat M., Matsui T., Dauge V., et al. Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. J Neurosci 22 (2002) 2005-2011
30. Price D.D., von der G.A., Miller J., Rafii A., and Price C. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesth Analg 64 (1985) 801-806
31. Pu S.F., Zhuang H.X., and Han J.S. Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor. Brain Res 657 (1994) 159-164
32. Rehfeld J.F., Holst J.J., and Jensen S.L. The molecular nature of vascularly released cholecystokinin from the isolated perfused porcine duodenum. Regul Pept 3 (1982) 15-28
33. Rivlin A.S., and Tator C.H. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg 47 (1977) 577-581
34. Schmidt B.L., Tambeli C.H., Barletta J., Luo L., Green P., Levine J.D., et al. Altered nucleus accumbens circuitry mediates pain-induced antinociception in morphine-tolerant rats. J Neurosci 22 (2002) 6773-6780
35. Suberg S.N., Culhane E.S., Carstens E., and Watkins L.R. The potentiation of morphine-induced inhibition of spinal transmission by proglumide, a putative cholecystokinin antagonist. Ann N Y Acad Sci 448 (1985) 660-662
36. Tortorici V., Nogueira L., Salas R., and Vanegas H. Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats. Pain 102 (2003) 9-16
37. Valverde O., Blommaert A.G., Fournie-Zaluski M.C., Roques B.P., and Maldonado R. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. Eur J Pharmacol 286 (1995) 79-93
38. Valverde O., Maldonado R., Fournie-Zaluski M.C., and Roques B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270 (1994) 77-88
39. Vanderhaegen J.J., Signeau J.C., and Gepts W. A new peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257 (1975) 604-605
40. 3H-etorphine binding to rat brain opiate receptors. Life Sci 45 (1989) 117-123
41. Wang X.J., and Han J.S. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors. J Neurochem 55 (1990) 1379-1382
42. Wank S.A. Cholecystokinin receptors. Am J Physiol 269 (1995) G628-G646
43. Watkins L.R., Kinscheck I.B., and Mayer D.J. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res 327 (1985) 169-180
44. Xie J.Y., Herman D.S., Stiller C.O., Gardell L.R., Ossipov M.H., Lai J., et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 25 (2005) 409-416